27 patients suffering from either extensive alopecia areata (n = 5) or alopecia totalis (n = 22) were treated topically with diphencyprone, a new potent contact allergen. The duration of treatment ranged from 4 to 17 months. Unilateral induction of hair growth after unilateral treatment was observed in 23 patients. A continuous response after continuous treatment has been observed so far in 18 of these patients. Thus, diphencyprone was found to be as effective as DNCB or squaric acid dibutylester in the treatment of alopecia areata. Unlike DNCB, diphencyprone is not mutagenic in the Ames test. Compared with squaric acid dibutylester, diphencyprone is more stable and thus more suitable for storage when dissolved in acetone. Further investigative evaluation of diphencyprone may show whether this drug is suitable for a more general use in the treatment of severe forms of alopecia areata.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.